(NASDAQ: ZYME) Zymeworks's forecast annual revenue growth rate of 17.29% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 97.98%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.8%.
Zymeworks's revenue in 2025 is $134,481,000.On average, 13 Wall Street analysts forecast ZYME's revenue for 2025 to be $9,340,347,809, with the lowest ZYME revenue forecast at $7,664,009,447, and the highest ZYME revenue forecast at $12,729,694,433. On average, 14 Wall Street analysts forecast ZYME's revenue for 2026 to be $17,695,098,464, with the lowest ZYME revenue forecast at $7,046,233,859, and the highest ZYME revenue forecast at $28,961,738,658.
In 2027, ZYME is forecast to generate $14,159,072,233 in revenue, with the lowest revenue forecast at $5,060,446,429 and the highest revenue forecast at $23,573,508,210.